Researchers are reevaluating the approach to biomarkers in gastric cancer immunotherapy, considering factors beyond the tumor itself. This shift in strategy is part of a broader trend of exploring new paradigms in oncology, with recent discussions and findings presented at the ASCO 2025 annual meeting. The reexamination of various aspects of cancer biology, including tumor microenvironments and immunological control, may lead to new approaches in cancer treatment.